Longevity research credibility now hinges on randomized trial endpoints: rapamycin and senolytic human data grow, yet no intervention has extended human lifespan in an RCT
Longevity science faces a harder test now: human trials, not mouse data. The PEARL trial found low dose rapamycin was well tolerated over a year in adults over 50, with modest biomarker changes. No intervention has extended human lifespan in a randomized trial. Source: Aging.
Longevity science has quietly changed the question it is trying to answer. For most of the past decade, the debate was whether a compound did anything measurable in cells or animals. The work now underway asks something harder: whether controlled trials in people show a durable, repeatable benefit. Rapamycin is the clearest case. The PEARL trial reported that low dose intermittent dosing was well tolerated over a year in healthy adults over 50, with modest changes in markers of biological aging. Separately, senolytic combinations such as dasatinib plus quercetin are being tested for their ability to clear senescent cells that accumulate with age. The part that rarely makes headlines is the most important. No intervention has yet been shown to extend human lifespan in a randomized controlled trial. That threshold, not another mouse study, is what separates a field that can treat aging from one that can only describe it. Sources: Aging, Healthspan 2025 review.